RxDoctor Payments Data

Miranda Gruenberg, PA

Physician Assistant · Avondale, AZNPI 1841444734

Payments from drug & device makers

$4,230in general payments, 2019–2025

Across 180 payments — averaging $23.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Biohaven Pharmaceuticals, Inc.$938
  • Novo Nordisk$543
  • AstraZeneca$379
  • Boehringer Ingelheim$261
  • Biohaven Pharmaceutical Holding Company Ltd.$125
  • plus $868 from 18 others

What the payments were for

  • Consulting fees$80019%
  • Food & beverage$3,40080%
  • Education$301%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,230 in reported general payments places this provider in the 90th percentile of 2,888 physician assistant providers in Arizona.

See all physician assistant providers in Arizona

Medicare billing

Part B allowed, 2024
$23,766
Medicare patients
116
Services billed
456

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide14$19,557
OzempicSemaglutide18$18,562
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$9,092
Bupropion XlBupropion Hcl16$810
Rosuvastatin Calcium63$720
Atorvastatin Calcium62$662
Losartan Potassium59$595
Pantoprazole Sodium38$567
Gabapentin22$555
Escitalopram Oxalate24$508
Trazodone Hcl41$460
Metoprolol Succinate18$320
Sertraline Hcl41$313
Levothyroxine Sodium52$277
Omeprazole15$250

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$86$19,55714 claims
Novo NordiskOzempic$543$18,56218 claims
GSKTrelegy Ellipta$78$9,09212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,888 physician assistant providers in Arizona.

Other physician assistant in Avondale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →